Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®

As biosimilars enter the market, comparisons of product quality are needed. Manufacturing differences may lead to differences in critical quality attributes, which affect efficacy. Therefore, critical quality attributes (structure and biological activity) of Remicade® and of 2 biosimilar products (F...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Changsoo, Jeong, Min, Lee, JongAh Joanne, Seo, Saebom, Cho, Sung Chun, Zhang, Wei, Jaquez, Orlando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540080/
https://www.ncbi.nlm.nih.gov/pubmed/28640663
http://dx.doi.org/10.1080/19420862.2017.1337620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540080/
https://www.ncbi.nlm.nih.gov/pubmed/28640663
http://dx.doi.org/10.1080/19420862.2017.1337620

Ejemplares similares